Overview

Biodel's proprietary VIAdel™ technology allows for a more effective delivery of endocrine therapeutics as well as increased efficacy and safety. This patented technology is applicable to a wide range of peptides, proteins and other macromolecules. Biodel's lead drug candidates VIAject™, a very rapid-acting injectable insulin and VIAtab™, a very rapid acting oral sub-lingual insulin utilize VIAdel™ technology. Additionally, Biodel is developing other therapies, such as VIAmass™ and VIAcal™, to treat a variety of endocrine disorders based on the VIAdel™ technology. All of Biodel's proprietary technologies and products have been developed in-house and patents have been filed.